ADI SBIR Phase 2: Development of a Serological Test for Herpes Simplex Type 1 and 2 Infections 75N93024C00044 / Topic 133.
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new requirement, set aside for total small business, to continue product development of a serological test that detects Herpes Simplex Virus and differentiates Type 1 from Type 2 infections, procured as ADI SBIR Phase 2 contract 75N93024C00044 under Topic 133 and classified under NAICS 541715. The requirement calls for a rapid, inexpensive test with high sensitivity and specificity, building on successfully completed early-stage research, because existing tests have insufficient sensitivity and specificity and the western blot assay, the current standard, is too costly and time consuming for widespread use. The estimated solicitation release date is 2026-09-01 and the estimated award date is 2026-10-01, both of which precede this 2026-11-14 posting.
The estimated award value range is $1.5 million to $3 million. Points of contact are Jonathan Glock (jglock@niaid.nih.gov), listed under the National Institutes of Health, and Callie Prassinos, Contracting Officer, at callie.prassinos@nih.gov or +1 240-669-5155.
Forecast text
An application to continue the product development of this successfully completed early-stage research for a diagnostic to detect Herpes Simplex Virus and differentiate between type 1 and type 2 infections in people. Existing tests have insufficient sensitivity and specificity, while the western blot assay, the current standard, is too costly and time consuming for widespread use. A rapid, inexpensive test that can detect and distinguish type1 and type 2 infections with high sensitivity and specificity is needed to improve medical care and public health surveillance of these infections.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast